Single-agent checkpoint inhibitor treatments in PD-L1-positive metastatic prostate cancers achieved positive outcomes in only a small percentage of patients, and in PD-L1-negative malignancies, the outcomes were even worse [254]. The gene discussed is CD274; the disease is metastatic prostate carcinoma.